Library Subscription: Guest
Critical Reviews™ in Oncogenesis

Published 4 issues per year

ISSN Print: 0893-9675

ISSN Online: 2162-6448

SJR: 0.395 SNIP: 0.322 CiteScore™:: 2.5 H-Index: 54

Indexed in

Clinical Trials in Non-Small Cell Lung Cancer with Biomarker-Driven Treatment Allocation: Ready or Not, Here We Come

Volume 20, Issue 5-6, 2015, pp. 339-347
DOI: 10.1615/CritRevOncog.v20.i5-6.70
Get accessGet access

ABSTRACT

Lung cancer is the leading cause of cancer mortality. Great advances in non-small cell lung cancer therapy have been seen in the last decade, beginning with the success in treating lung cancer harboring EGFR mutations and ALK-gene rearrangements. The potential of these biomarker-driven therapies has propelled research in biomarker targeted approaches to the forefront of lung cancer research. The successful development of immunotherapeutic agents targeting PD-L1 and PD-1 with an associated non-genomic biomarker has opened a new front in the effort for targeted approaches. Although early-phase lung cancer studies have hinted at the potential to use biomarkers to select patients for allocation to treatment in the conduct of clinical trials, data from late-phase studies have tempered expectations. The data leave unclear the wisdom of routinely restricting enrollment on lung cancer clinical trials to biomarker restricted populations, particularly non-genomic biomarkers.

CITED BY
  1. Masciale Valentina, Banchelli Federico, Grisendi Giulia, D’Amico Roberto, Maiorana Antonino, Stefani Alessandro, Morandi Uliano, Dominici Massimo, Aramini Beatrice, New Perspectives in Different Gene Expression Profiles for Early and Locally Advanced Non-Small Cell Lung Cancer Stem Cells, Frontiers in Oncology, 11, 2021. Crossref

  2. Bajpai Manisha, (David) Zhou Zhongren, Biomarkers of Esophageal Cancers and Precancerous Lesions, in Inflammation, Infection, and Microbiome in Cancers, 2021. Crossref

  3. van Bijsterveldt Linda, Durley Samuel C., Maughan Tim S., Humphrey Timothy C., The Challenge of Combining Chemo- and Radiotherapy with Checkpoint Kinase Inhibitors, Clinical Cancer Research, 27, 4, 2021. Crossref

  4. Rohilla Suman , Singh Mahaveer , Alzarea Sami I. , Almalki Waleed Hassan, Al-Abbasi Fahad A. , Kazmi Imran, Afzal Obaid , Altamimi Abdulmalik Saleh Alfawaz , Singh Sachin Kumar, Chellappan Dinesh Kumar, Dua Kamal , Gupta Gaurav, Recent Developments and Challenges in Molecular-Targeted Therapy of Non-Small-Cell Lung Cancer , Journal of Environmental Pathology, Toxicology and Oncology, 42, 1, 2023. Crossref

  5. Kumar Dileep, Thakar Snehal, Bansode Deepali Amol, Rai Gopal Kumar, Prospects and Challenges in the Treatment of Solid Tumors, in Polymeric nanoparticles for the treatment of solid tumors, 71, 2022. Crossref

Begell Digital Portal Begell Digital Library eBooks Journals References & Proceedings Research Collections Prices and Subscription Policies Begell House Contact Us Language English 中文 Русский Português German French Spain